Introduction
============

Despite improvements in ventilation strategies, acute respiratory distress syndrome (ARDS), which is the most severe form of acute lung injury (ALI), is associated with 40% ([@b13-btt-1-465]) and a 80% mortality in mechanically ventilated hematological patients ([@b24-btt-1-465]).

Alveolar fibrin deposition is an important feature of ARDS. The alveolar epithelium is capable of initiating intra-alveolar coagulation following exposure to inflammatory stimuli and may thus contribute to intra-alveolar fibrin deposition in ARDS ([@b3-btt-1-465]). The mechanisms that contribute to disturbed alveolar fibrin turnover are localized tissue factor-mediated thrombin generation and depression of bronchoalveolar urokinase plasminogen activator (uPA)-mediated fibrinolysis caused by the increase of plasminogen activator inhibitors ([@b26-btt-1-465]). Furthermore, a reduced supply of uPA inhibits lung epithelial cell function, since uPA has been shown to activate major intracellular signaling pathways such as tyrosine phosphorylation of Stat3 ([@b27-btt-1-465]). Further increased alpha 2-antiplasmin levels shift the alveolar hemostatic balance towards a procoagulant state ([@b16-btt-1-465]).

The natural protein C anticoagulant pathway is a vital system that limits the activation of hemostasis and has anti-inflammatory effects ([@b17-btt-1-465]; Dahlback and Villoutreix 2006; [@b10-btt-1-465]; [@b20-btt-1-465]). The alveolar epithelium may therefore modulate intra-alveolar fibrin deposition through activation of protein C.

In inflammatory lung disease the pulmonary host defense is downregulated, as observed in ARDS ([@b15-btt-1-465]).

It is therefore imperative that a new adjunctive intervention in ARDS does not further interfere with the immunocompetent cells of the lungs, ie, with alveolar macrophages or recruited neutrophils. Activated neutrophils accumulate in the lungs during severe infection and inflammation and further contribute to pulmonary dysfunction and mortality ([@b1-btt-1-465]).

These well described pathophysiological aspects of acute pulmonary inflammation in ARDS with fibrin formation, proinflammatory cytokine production, pulmonary cellular host defense, and neutrophil recruitment are all potential targets of a new treatment paradigm such as inhaled APC.

We describe here for the first time the effect of inhaled APC in a patient with severe ARDS.

Patient history
===============

A 48-year-old woman was treated with chemotherapy for a T-cell lymphoma present in mediastinum, bone marrow, retroperitoneum, and in all peripheral lymph node regions. After five courses of chemotherapy, a partial response with reduction in size of the lymphomas was noted.

While neutropenic after the last course of chemotherapy, she developed fever and clinical signs of pneumonia with lung infiltrates on chest X-ray. One week earlier, she was found to be Epstein barr virus (EBV)--PCR positive in peripheral blood with a high titer (520,000 copies/mL).

The patient subsequently developed respiratory insufficiency and was intubated and admitted to the intensive care unit (ICU), where she was mechanically ventilated. At the same time, the EBV-titer had dropped spontaneously to 100,000 copies/mL, but when a suspected lymphoproliferative disorder induced by EBV was indicated, the patient was treated with anti-CD-20 antibody (Mabthera).

The patient fulfilled the criteria for severe ARDS with a PaO~2~/FiO~2~ ratio of 55 mmHg and chest X ray with diffuse infiltrates. At ICU admittance she was diagnosed with septic shock in need of noradrenaline (NA) infusion combined with methylprednisolone infusion as a shock reversal therapy.

On ICU admission the patient had multi-organ dysfunction syndrome (MODS) with respiratory and hemodynamic failure, and liver and renal dysfunction. Administration of broad spectrum antibiotics began. On day 2 in the ICU, the PaO~2~/FiO~2~ ratio was unchanged and the patient was still in septic shock. Infectious biomarkers increased but no infectious microorganism was identified at any time.

Lung mechanics were dominated by severely reduced compliance irrespective of any lung protective ventilator setting or recruitment procedures including positioning in a prone position or administration of prostacycline. The optimal ventilator setting was pressure controlled mode with a PEEP 10 cm H~2~O and pressure level 25 cm H~2~O.

Blood gases throughout were characterized by respiratory acidosis with a pH = 7.29. Systemic steroid administration had no effect on pulmonary function.

Because of the patient's acute life-threatening state as a result of severe hypoxemia and the lack of response to conventional intervention, an experimental therapy with inhalation of activated protein C (APC (drotrecogin alpha activated \[Xigris^®^, Eli Lilly, USA\]) was commenced on day 4. An institutional review board (IRB) of the National University Hospital of Copenhagen consented to initiate the intervention which was also accepted by the patient's husband after informed consent. A dose schedule of 190 μg APC/kg 3 times a day was administered via a micropump nebulizer (Aeroneb^®^) which minimizes drug inactivation, in contrast to jet and ultrasound nebulizers which apply heat and shear stress.

The treatment was scheduled to last 7 days, ie, 21 doses in total. After 4 days (ICU day 8) there was a clear resolution of the infiltrates on chest X ray and of the PaO~2~/FiO~2~ ratio, which increased from 55 to 83 mmHg. After 6 days the NA infusion was weaned off and the chest film showed further reduction of infiltrates. The PaO~2~/FiO~2~ ratio was further increased to 131 mmHg and then to 155 mmHg at the end of inhalation, with APC corresponding to a 138% increase (see [Figure 1](#f1-btt-1-465){ref-type="fig"}). After 7 days the renal and liver dysfunction was reduced and a stable circulation without need of vasopressures was obtained.

No adverse effects of the APC inhalation therapy were observed and specifically no "bloody" lavage fluid was seen from the tracheal tube. Bronchoalveolar lavage (BAL) and a transbronchial needle biopsy was performed in the ICU on day 14. The biopsy showed diffuse alveolar inflammation corresponding to the organizing phase of diffuse alveolar damage, and signs of bronchiolitis affecting the bronchioli. There was no evidence of lymphoproliferative disease in the lung biopsy. BAL fluid cultures were negative for bacteria, yeast, mold, and virus. On day 16, a CT scan of the abdomen showed new mediastinal and retroperitoneal lymph nodes. In spite of the temporary clinical improvement with improved oxygenation capacity and opacities on chest X-ray, the patient died in the ICU on day 22 from cardiac arrest. Postmortem section was not granted by her husband.

Discussion
==========

Management of ARDS is difficult due to the frequently life-threatening hypoxemia ([@b32-btt-1-465]). For many years ARDS has been treated with corticosteroids, an approach which has now been shown to be disappointing ([@b33-btt-1-465]). In this patient, however, the corticosteroids were administered as a shock-reversal therapy and not as a symptomatic ARDS therapy. Further symptomatic intervention in ARDS has been the subject of many other randomised studies including treatment options such as antioxidants, inhaled surfactant and vasodilators like nitric oxide, and conservative fluid management of these critically ill patients. These interventions were unsuccessful in reducing the mortality of this potentially lethal disease ([@b38-btt-1-465]). In spite of therapy to treat any underlying causative factor, standard symptomatic interventions in ARDS with lung protective ventilation, lung recruitment, use of an inhaled vasodilator with prostacyclin (PGI~2~), and positioning in the prone position, the patient did not respond in respect to respiratory failure or oxygenation capacity. The ARDS condition also failed to respond to systemic steroid therapy. The APC in the present case history was not administered because Severe Sepsis was indicated, but as an experimental therapy for severe pulmonary dysfunction. Since this is a "first in man" therapy, and no evidence based therapy for ARDS exists ([@b38-btt-1-465]), an experimental attempt was initiated in order to modify or treat the diffuse lung injury. The therapy with inhaled APC for seven days seemed to demonstrate a clear response, with reduction in opacities on chest X ray and with a 138% increase in oxygenation capacity on day 7 as reflected by the PaO~2~/FiO~2~ ratio.

This patient died suddenly from a cardiac arrest. Recurrence of malignant lymphoma may have contributed to this event. Another component of the negative outcome might have been the result of initiating the inhalation with APC at a too advanced and less responsive phase of the ARDS course. At the time of death, there was no systemic or local pulmonary adverse effects of iAPC, ie, no signs of bleeding systemically or locally in the lung, ie, alveolar hemorrhage was not present.

ARDS and APC
------------

Endogenous protein C can be activated by thrombomodulin (TM) in the distal airways as well as in the microcirculation (Dahlback and Villoutreix 2006; [@b10-btt-1-465]; [@b20-btt-1-465]). In the periphery of the lung an epithelial protein C receptor (EPCR), located on alveolar type I and II cells in the small airways mediates the endogenous pulmonary APC response ([@b35-btt-1-465]). Inflammation induced by lipopolysaccharide (LPS) causes suppression of the PC pathway, as indicated by increased concentration of soluble TM and decreased concentration of PC and APC in bronchoalveolar lavage fluid (BALF) ([@b19-btt-1-465]).

In a study of 45 patients with ALI/ARDS, resulting from septic and nonseptic causes, the concentration of TM in BALF was more than twofold higher than simultaneous plasma levels, suggesting that local production in the lung, and increased edema fluid TM level, was associated with worse clinical outcomes ([@b36-btt-1-465]). Deficient intra-alveolar activation of protein C may aggravate the severity of ARDS by enhancing fibrin deposition via localized pulmonary tissue factor-mediated thrombin generation, and depression of bronchoalveolar urokinase plasminogen activator-mediated fibrinolysis, caused by the increase of plasminogen activator inhibitor (PAI)-1 ([@b26-btt-1-465]). Therefore, the protein C system may be a potential therapeutic target, using supplementary inhalation of APC in patients with ALI/ARDS to compensate for the innate APC deficiency.

In mice exposed to LPS, inhalation of APC was associated with a dose-dependent decrease in coagulation, inflammation markers in BAL fluid, reduced protein leakage into the alveolar space and improved lung function ([@b29-btt-1-465]).

These findings provide new evidence that inhaled activated protein C may modify alveolar fibrin deposition in ARDS ([@b32-btt-1-465]) as seen in the positive clinical response in the present patient.

Intravenous vs inhalation administration of APC
-----------------------------------------------

Intravenously administered recombinant human activated protein C (rhAPC) in acute lung injury after bacterial challenge significantly attenuated the fall in PaO~2~/FiO~2~ ratio, improved the lung mechanics and limited the induced lung tissue injury ([@b34-btt-1-465]). The APC, however, most likely exerts its effect both through inhibition of coagulation, and by inhibiting inflammation and apoptosis, by binding to its receptor EPCR, located in the airspaces. This result implies that the multiple targets for APC in ARDS are located in the airspaces (see [Figure 1](#f1-btt-1-465){ref-type="fig"}).

In order to obtain a sufficiently high alveolar concentration of APC, the IV dose rate must be sufficiently high, taking into account several factors. In order to reach sufficient alveolar APC concentration, the IV dosing must overcome the inactivation of the two serpins, alpha1-anti trypsin and the protein C inhibitor (PCI), and also the very short half-life of 13 minutes of APC when administered intravenously ([@b4-btt-1-465]). Furthermore, the APC molecule is quite large, ie, 55 kDa with 461 amino acids with a corresponding high diffusion barrier across the alveolo-capillary membrane to the airway receptors. All these factors limit the efficiency of an IV dose when the target is the airways. Once the IV dose reaches the air space, APC is further metabolised by alveolar proteolytic enzymes. It therefore seems rational also to inhale APC when the therapeutic target is the lung airspaces in acute respiratory injury like ARDS, in order to overcome the adverse effects of IV dosing.

The dosing of inhaled APC in the present patient case was based on the same dosing regime as in the PROWESS study ([@b5-btt-1-465]) of 24 μg/kg/hr, corresponding to a total dose for 24 hours of 576 μg/kg; divided into three inhalation doses. This treatment corresponds to a single inhaled dose of 190 μg/kg rAPC.

We predicted that a dose of 190 μg/kg per inhalation, would give rise to a suitably lower alveolar concentration, corresponding to 20% of the inhaled APC dose deposited using the micropump nebulizer Aeroneb ([@b9-btt-1-465]). The metabolism of APC has been well described; however, the intrapulmonary metabolism after inhaled APC has not been elucidated.

An increased metabolism of APC is likely in inflammatory pulmonary conditions, because elevated levels of neutrophil, and macrophage-derived proteolytic enzymes like neutrophil elastase and cathepsin, have been documented in ARDS patients ([@b25-btt-1-465]). Furthermore, because the neutralizing protein C Inhibitor (PCI) is a smaller molecule, it readily diffuses into the alveolar space where it subsequently neutralizes APC, a process which is enhanced in inflammatory lung disease, as revealed by increased concentrations of bronchoalveolar lavage fluid levels of TAFI and PCI ([@b12-btt-1-465]). A high APC dose would give rise to a 'spill over' of drug to the systemic circulation with detectable increase in APTT. Such an increase however could not be demonstrated in the present patient. In short, it seems that an inhaled dose of 190 μg/kg in each inhalation is a realistic moderate dose. In a systematic proof of concept study, APC kinetics will be included.

We chose to extend the dose length from the 4-day dose scheme applied in the prowess study ([@b5-btt-1-465]) to 7 days in the present patient, taking into account the ongoing pathophysiology of the ARDS and the relatively long recovery time of ARDS.

In the present study a micropump nebulizer was selected, because it has been shown to produce aerosolized protein samples which retain both structural integrity and biological activity ([@b22-btt-1-465]). This decision is in keeping with the study of aerosolized APC using the same nebulizer where coagulation factors like TAT complex and the cytokines TNF and IL-6 were reduced, corresponding to a preserved activity of APC aerosol ([@b29-btt-1-465]). It is therefore likely that the inhaled APC retains its activity after aerosolization using a micropump nebulizer.

APC and diffuse lung injury (DLI)
---------------------------------

Pulmonary complications like noninfectious diffuse lung injury (DLI) in hematological patients like the patient case -- a severe form of ARDS -- has a high incidence in hematological patients ([@b18-btt-1-465]). The histopathology of DLI includes diffuse epithelial alveolar damage with hyaline membranes, lymphocytic bronchiolar inflammation and bronchiolitis obliterans with organizing pneumonia (BOOP) ([@b37-btt-1-465]). The survival rate for critically ill hematological patients with DLI requiring mechanical ventilation has been reported to be well below 20% ([@b28-btt-1-465]; [@b24-btt-1-465]). This patient died suddently from a cardiac arrest; both the ARDS and the malignant lymphoma may have contributed to this event. Another component of the negative outcome was the initiation of the inhalation with APC at a late and less responsive phase of the ARDS course. At the time of death, there was no systemic or local pulmonary adverse effects of iAPC with no signs of bleeding systemically or locally in the lung, ie, alveolar hemorrhage was not present.

This patient had a component of bronchiolitis as seen in the lung biopsy. The pulmonary clinical response in the present case could partially be explained by the immunomodulatory effect of activated protein C, which has been shown to reduce the peribronchiolar lymphocytic migration ([@b11-btt-1-465]). This effect matches the findings of an inhibition of immunologic and inflammatory responses induced by Th2 produced cytokines in a mouse model of asthma after intratracheally administered APC ([@b39-btt-1-465]).

Pulmonary host defense and APC
------------------------------

The pulmonary host defense is reduced in ARDS with increased apoptosis gene expression and reduced TLR gene mRNA expression in airway cells ([@b15-btt-1-465]). Mechanical ventilation with high FiO~2,~ results in further impairment in pulmonary innate immunity through suppression of local GM-CSF expression of alveolar epithelial cells due to hyperoxic stress ([@b2-btt-1-465]). It is therefore important when introducing a novel therapy such as aerosolized APC, that it does not further interfere with the pulmonary host defense.

Inhalation of APC interacts with the inflammatory and coagulation, a response which may impede the primary host defense mechanisms ([@b23-btt-1-465]). Prior to introduction of a new therapy like inhalation of APC, evaluation of host defense, such as phagocytotic activity of alveolar macrophages, apoptosis of cellular host defense and expression of alveolar recognition receptors, ie, Toll-like receptors must be taken into account. An in-vitro study of activated protein C showed that the lifespan of human macrophages was prolonged, with unaltered phagocytotic function towards both Gram-positive and Gram-negative bacteria, and persistent adherence capabilities to LPS stimulated cells, promoting and maintaining antimicrobial properties while limiting damage to host tissue ([@b30-btt-1-465]). There is no documentation of the interference of APC with TLR receptor expression, but in the study of LPS challenge, APC reduced mortality in murine endotoxemia and models of severe sepsis ([@b14-btt-1-465]) and in the study of pneumonia, APC did not seem to interact with bacterial clearance ([@b6-btt-1-465]). This study also showed that administration of APC improved the outcome for patients with severe sepsis in spite of positive cultures in a majority of the included septic patients ([@b5-btt-1-465]). Finally APC has an antiapoptotic effect ([@b10-btt-1-465]) which is considered an essential therapeutic target treating infectious conditions ([@b8-btt-1-465]).

Accumulation of activated neutrophils into the airspaces during severe infection contributes to organ dysfunction in ARDS. It has been shown that APC modulates the neutrophil responses due to the expression of an APC receptor on these cells ([@b31-btt-1-465]), and that intravenous APC reduced leukocyte accumulation, and neutrophil chemotaxis into the airspaces without inducing immunosuppression ([@b21-btt-1-465]).

Therefore, in general APC does not seem to have a negative affect on pulmonary host defense. On the contrary, inhaled APC most likely represents a valuable new treatment which reduces severity of ARDS, but without interfering with the pulmonary host defense.

Conclusion
==========

A new symptomatic therapy, involving intrapulmonary administration of aerosolized APC is proposed and illustrated by a case with a positive pulmonary clinical response. No adverse effects could be registered during the 7-day therapy. From a theoretical viewpoint, inhaled APC with its anticoagulatory, profibrinolytic, antiinflammatory and antiapoptotic effect, including reduced neutrophil recruitment into the airspaces, has all the essential properties to counteract the pathophysiological changes seen in ARDS. Furthermore, inhaled APC seems not to interfere with the pulmonary host defense. Therefore we suggest that ARDS is best treated from the "air side" with aerosolized APC, because the innate intrapulmonary PC-APC axis is disrupted in inflammatory lung conditions like ARDS and the multiple effects of iAPC are mediated via the targets in the airspaces. We conclude that inhaled APC could become a new treatment option in patients with ALI or ARDS. This hypothesis should be substantiated in a study of a larger series of ARDS patients.

Key messages
============

1.  -- Inhaled APC has multiple effects to counteract the well described pathophysiological ARDS changes, as illustrated in a patient case.

2.  -- It seems that inhaled APC does not interfere with pulmonary host defense.

3.  -- Inhaled APC might be a new ideal adjunctive intervention in ARDS combined with therapy of underlying disease, a suggestion which should be substantiated in a larger series of patients.
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![Chest X-ray of the patient at the start of the inhalation of APC (**A**) and after 7 days of inhalation with APC (**B**).](btt-1-465f1){#f1-btt-1-465}

![Illustration of the potential multiple effects of inhaled activated protein C (iAPC) in ARDS in relation to the underlying pathophysiology of ARDS. Inhaled APC (1) inhibits coagulation (Factor Va and VIIIa) (2) and enhances fibrinolysis (3). Further iAPC has an anti-inflammatory effect and anti-apoptotic effect exerted via its APC receptor (EPCR) on the alveolar macrophage, epithelial cell and finally at the site of small airways (4) and reduces tissue factor expression via inhibition of the transnuclear NFKB translocation (5). Finally iAPC inhibits neutrocyte recruitment from the circulation to the airspaces (6) without interfering with their host function. The numbers 1--6 refer to the multiple points of action of iAPC.\
**Abbreviations:** AF, Alveolar macrophage; EPCR, Epithelial protein C receptor; FVII, Coagulation factor VII; SA cell, Mucosal cell of small airways.](btt-1-465f2){#f2-btt-1-465}
